{"title":"Indicators of mammary gland secretion in cows with subclinical mastitis when using interferon-λ","authors":"V. I. Zimnikov, O. Manzhurina, E. V. Tyurina","doi":"10.52419/issn2072-2419.2022.4.401","DOIUrl":null,"url":null,"abstract":"The largest number of currently produced drugs for the treatment of mastitis in lactating cows contain antimicrobial components (antibiotics) as active substances. The studies were carried out on Red-Motley Holstein cows, in which subclinical mastitis was diagnosed. The animals selected for the experiment were divided into three groups. The first group included 8 animals, they were not treated and served as a negative control. In the second group, 10 cows were selected for treatment with Biferon-B for three days once a day at a dose of 10 ml. per animal. The animals of the third group were simultaneously administered interferon-λ and BiferonB intramuscularly, 10 ml each during those days. According to the results of clinical studies, it was found that no recovery was recorded in the animals in the negative control group. In the group of animals where Biferon-B was used, the efficacy of treatment was 60.0%, and with the combined use of Biferon-B and interferon-λ, the effect of treatment was 83.3%. In these animals, the number of somatic cells decreased by 14.3 times, the concentration of neutrophils – by 2.6 times, the amount of total Ig - by 67.5%, CIC - by 61.5%, against the background of an increase in the number of lymphocytes by 6.0 times, monocytes - by 2.1 times and lysozyme - by 45.3%, and the bacterial contamination of the udder secretion also decreased to 0.08 thousand CFU/ml, which was by 120 times less compared to the initial state. Only Escherichia coli has been isolated from the udder secretion in 20.0% of cases that confirms the clinical efficacy of the treatment.","PeriodicalId":14419,"journal":{"name":"International Journal of Veterinary Medicine","volume":"77 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Veterinary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52419/issn2072-2419.2022.4.401","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The largest number of currently produced drugs for the treatment of mastitis in lactating cows contain antimicrobial components (antibiotics) as active substances. The studies were carried out on Red-Motley Holstein cows, in which subclinical mastitis was diagnosed. The animals selected for the experiment were divided into three groups. The first group included 8 animals, they were not treated and served as a negative control. In the second group, 10 cows were selected for treatment with Biferon-B for three days once a day at a dose of 10 ml. per animal. The animals of the third group were simultaneously administered interferon-λ and BiferonB intramuscularly, 10 ml each during those days. According to the results of clinical studies, it was found that no recovery was recorded in the animals in the negative control group. In the group of animals where Biferon-B was used, the efficacy of treatment was 60.0%, and with the combined use of Biferon-B and interferon-λ, the effect of treatment was 83.3%. In these animals, the number of somatic cells decreased by 14.3 times, the concentration of neutrophils – by 2.6 times, the amount of total Ig - by 67.5%, CIC - by 61.5%, against the background of an increase in the number of lymphocytes by 6.0 times, monocytes - by 2.1 times and lysozyme - by 45.3%, and the bacterial contamination of the udder secretion also decreased to 0.08 thousand CFU/ml, which was by 120 times less compared to the initial state. Only Escherichia coli has been isolated from the udder secretion in 20.0% of cases that confirms the clinical efficacy of the treatment.